Dexamethasone infusion in community-acquired pneumonia

Phase 4

Completed

Conditions: 10019815
CAP
lung infection

Registration Number: NL-OMON35460

Lead Sponsor: Sint Antonius Ziekenhuis

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 300

Inclusion Criteria

Patients aged 18 to 100 years with a community-acquired pneumonia.
Criteria to determine a community-acquired pneumonia:
Chest radiograph showing new opacities
In combination with two of the following findings:
· Cough
· Production of sputum
· Temp >38,0 °C or <36,0 °C
· Audible abnormalities by chest examination compatible with pneumonia
· Leukocytosis (>10.000 cells/mm3), leftward shift (>10%) or leukopenia
(<4000 cells/mm3)
· CRP > 15 mg/l (three times upper limit of normal)

Exclusion Criteria

Immunocompromised patients:
· Patients with a known congenital or achieved immunodeficiency.
· Patients who received chemotherapy less than 6 weeks ago.
· Patients who received corticosteroids in the last 6 weeks.
· Patients who received immunosuppressive medication in the last 6
weeks. (like cyclosporine, cyclofosfamide, azathioprine)
· Patients with COPD who are on systemic corticosteroids for COPD.
· Patients who require ICU treatment.
. Patients who received a 13-valent pneumococcal conjugate vaccine within the last 30 days.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>- length of hospital stay </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- admission to ICU, inflammation markers and health performance<br /><br>- length of treatment with intravenous antibiotics<br /><br>- side-effects<br /><br>- lung function<br /><br>- mortality<br /><br>- prognostic value of serum ACE activity<br /><br>- analysis of cost savings and effectiveness<br /><br>- coagulation cascade in patients with CAP (pulmonary en intravascular)</p><br>